- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03879603
VRC 313: A Trivalent Virus-like Particle (VLP) Encephalitis Vaccine (WEVEE) in Healthy Adults
A Phase 1 Open Label, Dose-Escalation Clinical Trial to Evaluate the Safety and Immunogenicity of a Trivalent Virus-Like Particle (VLP) Encephalitis Vaccine, VRC-WEVVLP073-00-VP, in Healthy Adults
Western Equine Encephalitis Virus (WEEV), Eastern Equine Encephalitis Virus (EEEV), and Venezuelan Equine Encephalitis Virus (VEEV) are transmitted to humans by infected mosquitoes and can cause encephalitis (swelling of the brain) and other neurological manifestations, including fever, chills, discomfort, feeling sick, muscle pain and then headache, vomiting, restlessness, irritability, seizures, coma, and death.
Vaccines teach the body to prevent or fight an infection. When the body learns to fight an infection, this is called an immune response. Researchers developed a vaccine against Western, Eastern and Venezuelan equine encephalitis viruses to help the body make an immune response. There are no live or killed viruses in the vaccine, so you cannot get infected with any of these 3 viruses from getting the vaccine.
The experimental trivalent encephalitis vaccine, VRC-WEVVLP073-00-VP, is composed of Western equine encephalitis (WEE), Eastern equine encephalitis (EEE), and Venezuelan equine encephalitis (VEE) virus-like particles (VLP).
The purpose of this study is to test three doses (6 mcg, 30 mcg, and 60 mcg) of this experimental vaccine against Western, Eastern and Venezuelan equine encephalitis viruses.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a Phase 1, randomized, open-label, dose-escalation study to examine the safety, tolerability, and immune response of three doses (6 mcg, 30 mcg, and 60 mcg) of the WEVEE vaccine (VRC-WEVVLP073-00-VP) alone or with alum adjuvant (VRC-GENMIX083-AL-VP) in a 2-product administration regimen.
Eligible subjects were randomized to WEVEE alone (Groups 1, 3, and 5) or WEVEE plus alum (Groups 2, 4, and 6, respectively) in each dose group. No more than 1 subject was randomized and vaccinated per day for the first 3 subjects at each dose. If the 6 mcg dose of WEVEE was assessed as not showing safety concerns by a Protocol Safety Review Team (PSRT), randomization began for Groups 3 and 4 (30 mcg WEVEE without alum and with alum, respectively). In a second safety review conducted on the first 3 subjects to receive 30 mcg, if the 30 mcg dose of WEVEE was assessed as not showing safety concerns by the PSRT, randomization began for Groups 5 and 6 (60 mcg WEVEE without and with alum, respectively).
The product was administered in the upper arm muscle as an intramuscular (IM) injection via needle and syringe at Day 0 and 8 weeks later.
For all groups, solicited reactogenicity was evaluated using a 7-day diary card. Assessment of vaccine safety included clinical observation and monitoring of hematological and chemical parameters at clinical visits throughout the study.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Georgia
-
Decatur, Georgia, United States, 30030
- The Hope Clinic of the Emory Vaccine Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
A volunteer must have met all of the following criteria:
- Age 18 to 50 years
- Available for clinical follow-up through 36 weeks after randomization
- Able to provide proof of identity to the satisfaction of the study clinician completing the enrollment process
- Able and willing to complete the informed consent process
- Willing to donate blood for sample storage to be used for future research
- In good general health, without clinically significant medical history, and has satisfactorily completed screening
- Physical examination and laboratory results without clinically significant findings within the 28 days prior to randomization
Laboratory Criteria within 28 days prior to randomization:
- Hemoglobin within institutional normal range or accompanied by Principal Investigator (PI) or designee approval
- White blood cell (WBC) and differential either within institutional normal range or accompanied by PI or designee approval
- Total lymphocyte count: ≥800 cells/mm3
- Platelets: 125,000-500,000/mm3
- Alanine aminotransferase (ALT): ≤ 1.25 x upper limit of normal range
- Serum creatinine: ≤1.1 x upper limit of normal
- Negative for HIV infection by an FDA-approved method of detection
Criteria applicable to women of childbearing potential:
- Negative beta-human chorionic gonadotropin (β-HCG) pregnancy test (urine or serum) on day of randomization before receiving the study product
- Agrees to use an effective method of birth control, if sexually active, from at least 21 days prior to randomization through the last study visit.
Exclusion Criteria:
A volunteer was excluded if one or more of the following conditions applied:
Female-Specific Criteria
• Breast-feeding or planning to become pregnant while participating in the study
Volunteer received any of the following:
- More than 10 days of systemic immunosuppressive medications or cytotoxic medications within the 4 weeks prior to randomization or any within the 14 days prior to randomization
- Blood products within 16 weeks prior to randomization
- Immunoglobulin within 8 weeks prior to randomization
- Prior vaccinations with an investigational alphavirus vaccine
- Investigational research agents within 4 weeks prior to randomization or planning to receive investigational products while on study
- Live attenuated vaccines within 4 weeks prior to randomization
- Inactivated vaccines within 2 weeks prior initial study vaccine administration unless approved by the PI
- Current anti-tuberculosis (TB) prophylaxis or therapy
Volunteer has a history of any of the following clinically significant conditions:
- A history of confirmed or suspected viral encephalitis infection
- Serious reactions to vaccines that preclude receipt of study vaccinations as determined by the investigator
- Hereditary angioedema, acquired angioedema, or idiopathic forms of angioedema
- Asthma that is not well controlled
- Diabetes mellitus (type I or type II) with the exception of gestational diabetes
- Thyroid disease that is not well controlled
- Hypertension that is not well controlled
- Evidence of autoimmune disease or immunodeficiency
- Idiopathic urticaria within the last year
- Malignancy that is active or history of malignancy that is likely to recur during the study
- Bleeding disorder diagnosed by a doctor (e.g., factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or significant bruising or bleeding difficulties with intramuscular (IM) product administration or blood draws
- Seizure disorder other than: 1) febrile seizures, 2) seizures secondary to alcohol withdrawal more than 3 years ago, or 3) seizures or treatment for a seizure disorder within the last 3 years
- Asplenia, functional asplenia or any condition resulting in absence or removal of the spleen
- Psychiatric condition that precludes compliance with the protocol; past or present psychoses; or within 5 years prior to randomization, a history of suicide plan or attempt
- Any other chronic or clinically significant medical, psychiatric or social condition that, in the judgement of the investigator is a contraindication to protocol participation or impairs a volunteer's ability to give informed consent.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group 1: 6 mcg WEVEE vaccine
6 mcg of WEVEE vaccine (VRC-WEVVLP073-00-VP) administered IM on Day 0 and Week 8
|
VRC-WEVVLP073-00-VP is composed of 1:1:1 ratio of WEE, EEE, and VEE virus-like particles (VLP)
Other Names:
|
Experimental: Group 2: 6 mcg WEVEE vaccine + alum
6 mcg of WEVEE vaccine (VRC-WEVVLP073-00-VP) and 500 mcg of Alum (VRC-GENMIX083-AL-VP) administered IM on Day 0 and Week 8
|
VRC-WEVVLP073-00-VP is composed of 1:1:1 ratio of WEE, EEE, and VEE virus-like particles (VLP)
Other Names:
VRC-GENMIX083-AL-VP is an adjuvant
Other Names:
|
Experimental: Group 3: 30 mcg WEVEE vaccine
30 mcg of WEVEE vaccine (VRC-WEVVLP073-00-VP) administered IM on Day 0 and Week 8
|
VRC-WEVVLP073-00-VP is composed of 1:1:1 ratio of WEE, EEE, and VEE virus-like particles (VLP)
Other Names:
|
Experimental: Group 4: 30 mcg WEVEE vaccine + alum
30 mcg of WEVEE vaccine (VRC-WEVVLP073-00-VP) and 500 mcg of Alum (VRC-GENMIX083-AL-VP) administered IM on Day 0 and Week 8
|
VRC-WEVVLP073-00-VP is composed of 1:1:1 ratio of WEE, EEE, and VEE virus-like particles (VLP)
Other Names:
VRC-GENMIX083-AL-VP is an adjuvant
Other Names:
|
Experimental: Group 5: 60 mcg WEVEE vaccine
60 mcg of WEVEE vaccine (VRC-WEVVLP073-00-VP) administered IM on Day 0 and Week 8
|
VRC-WEVVLP073-00-VP is composed of 1:1:1 ratio of WEE, EEE, and VEE virus-like particles (VLP)
Other Names:
|
Experimental: Group 6: 60 mcg WEVEE vaccine + alum
60 mcg of WEVEE vaccine (VRC-WEVVLP073-00-VP) and 500 mcg of Alum (VRC-GENMIX083-AL-VP) administered IM on Day 0 and Week 8
|
VRC-WEVVLP073-00-VP is composed of 1:1:1 ratio of WEE, EEE, and VEE virus-like particles (VLP)
Other Names:
VRC-GENMIX083-AL-VP is an adjuvant
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Subjects Reporting Local Reactogenicity Signs and Symptoms For 7 Days After Each Product Administration
Time Frame: 7 days after each product administration, at approximately Week 1 and Week 9
|
Subjects recorded the occurrence of solicited symptoms on a diary card for 7 days after each study product administration and reviewed the diary card with clinic staff at a follow up visit.
Subjects were counted once for each symptom at the worst severity if they indicated experiencing the symptom at any severity during the reporting period.
The number reported for "Any Local Symptom" is the number of subjects reporting any local symptom at the worst severity.
Reactogenicity grading (Mild, Moderate, Severe) was done using the Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials (modified from FDA Guidance - September 2007).
|
7 days after each product administration, at approximately Week 1 and Week 9
|
Number of Subjects Reporting Systemic Reactogenicity Signs and Symptoms For 7 Days After Each Product Administration
Time Frame: 7 days after each product administration, at approximately Week 1 and Week 9
|
Subjects recorded the occurrence of solicited symptoms on a diary card for 7 days after each study product administration and reviewed the diary card with clinic staff at a follow up visit.
Subjects were counted once for each symptom at the worst severity if they indicated experiencing the symptom at any severity during the reporting period.
The number reported for "Any Systemic Symptom" is the number of subjects reporting any systemic symptom at the worst severity.
Reactogenicity grading (Mild, Moderate, Severe) was done using the Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials (modified from FDA Guidance - September 2007).
|
7 days after each product administration, at approximately Week 1 and Week 9
|
Number of Subjects With Abnormal Laboratory Measures of Safety
Time Frame: Day 0 through Day 252
|
Any abnormal laboratory results recorded as unsolicited adverse events (AEs) are summarized.
Safety laboratory parameters included hematology (hemoglobin, hemoglobin change from baseline, hematocrit, mean corpuscular volume (MCV), platelets, and white blood cell (WBC), red blood cell (RBC), neutrophil, lymphocyte, monocyte, eosinophil and basophil counts) and chemistry (alanine aminotransferase (ALT) and creatinine).
Complete blood count (CBC), differential, platelet, and ALT results were collected at screening (≤ 28 days before enrollment), Day 0 prior to study product administration (baseline), and at Days 14, 28, 56, 70, 84, 168 and 252.
Creatinine results were collected at screening, Day 0 and Day 56.
Institutional laboratory normal ranges as well as the Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventative Vaccine Clinical Trials (modified from FDA Guidance, September 2007) were used.
|
Day 0 through Day 252
|
Number of Subjects With One or More Unsolicited Non-Serious Adverse Events (AEs)
Time Frame: Day 0 through 4 weeks of each study product administration, up to Week 12
|
Unsolicited AEs and attribution assessments were recorded in the study database from receipt of the first study product administration through the visit scheduled for 4 weeks after each study product administration.
At other time periods between study product administrations and when greater than 4 weeks after the last study product administration, only serious AEs (SAEs reported as a separate outcome and in the AE module) and new chronic medical conditions that required ongoing medical management were recorded through the last study visit.
The relationship between an AE and the study product was assessed by the investigator based on clinical judgment and the definitions outlined in the protocol.
A subject with multiple experiences of the same event is counted once using the event of worst severity.
|
Day 0 through 4 weeks of each study product administration, up to Week 12
|
Number of Subjects With Serious Adverse Events (SAEs)
Time Frame: Day 0 through Day 252
|
SAEs were reported from receipt of first study product administration through the last expected study visit at Day 252.
The relationship between a SAE and the study product was assessed by the investigator based on clinical judgment and the definitions outlined in the protocol.
A subject with multiple experiences of the same event is counted once using the event of worst severity.
|
Day 0 through Day 252
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Antigen-specific Neutralizing Antibody Geometric Mean Titers (GMTs) at 4 Weeks After the Last Product Administration of VRC-WEVVLP073-00-VP (WEVEE) Alone Or With Alum Adjuvant
Time Frame: 4 weeks after the last product administration, at Week 12
|
WEVEE antigen-specific antibody responses as evaluated by virus-specific neutralization assays.
Eastern Equine Encephalitis Virus (EEEV), Venezuelan Equine Encephalitis Virus (VEEV) and Western Equine Encephalitis Virus (WEEV) neutralizing titers were assessed using a plaque reduction neutralization test (PRNT) at baseline and 4 weeks after the second study injection.
Geometric mean titers of the individual PRNT80 (80% plaque reduction neutralization) titer values are reported.
|
4 weeks after the last product administration, at Week 12
|
Percentage of Positive Responders at 4 Weeks After the Last Product Administration of VRC-WEVVLP073-00-VP (WEVEE) Alone Or With Alum Adjuvant
Time Frame: 4 weeks after the last product administration, at Week 12
|
A subject was a responder or met the threshold of a positive response if the post vaccination anti-Eastern Equine Encephalitis Virus (EEEV), Venezuelan Equine Encephalitis Virus (VEEV) or Western Equine Encephalitis Virus (WEEV) antibody titer was 10 or greater.
|
4 weeks after the last product administration, at Week 12
|
Collaborators and Investigators
Investigators
- Study Chair: Julie E Ledgerwood, DO, VRC/NIAID/NIH
- Study Chair: Grace Chen, MD, VRC/NIAID/NIH
Publications and helpful links
General Publications
- Chang LJ, Dowd KA, Mendoza FH, Saunders JG, Sitar S, Plummer SH, Yamshchikov G, Sarwar UN, Hu Z, Enama ME, Bailer RT, Koup RA, Schwartz RM, Akahata W, Nabel GJ, Mascola JR, Pierson TC, Graham BS, Ledgerwood JE; VRC 311 Study Team. Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial. Lancet. 2014 Dec 6;384(9959):2046-52. doi: 10.1016/S0140-6736(14)61185-5. Epub 2014 Aug 14.
- Akahata W, Yang ZY, Andersen H, Sun S, Holdaway HA, Kong WP, Lewis MG, Higgs S, Rossmann MG, Rao S, Nabel GJ. A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection. Nat Med. 2010 Mar;16(3):334-8. doi: 10.1038/nm.2105. Epub 2010 Jan 28.
- Coates EE, Edupuganti S, Chen GL, Happe M, Strom L, Widge A, Florez MB, Cox JH, Gordon I, Plummer S, Ola A, Yamshchikov G, Andrews C, Curate-Ingram S, Morgan P, Nagar S, Collins MH, Bray A, Nguyen T, Stein J, Case CL, Kaltovich F, Wycuff D, Liang CJ, Carlton K, Vazquez S, Mascola JR, Ledgerwood JE; VRC 313 Study Team. Safety and immunogenicity of a trivalent virus-like particle vaccine against western, eastern, and Venezuelan equine encephalitis viruses: a phase 1, open-label, dose-escalation, randomised clinical trial. Lancet Infect Dis. 2022 Aug;22(8):1210-1220. doi: 10.1016/S1473-3099(22)00052-4. Epub 2022 May 11.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- RNA Virus Infections
- Virus Diseases
- Infections
- Encephalitis, Arbovirus
- Encephalitis, Viral
- Central Nervous System Viral Diseases
- Central Nervous System Infections
- Infectious Encephalitis
- Arbovirus Infections
- Vector Borne Diseases
- Encephalomyelitis
- Togaviridae Infections
- Encephalitis
- Encephalomyelitis, Equine
- Encephalomyelitis, Eastern Equine
- Encephalomyelitis, Venezuelan Equine
- Encephalomyelitis, Western Equine
- Alphavirus Infections
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Immunologic Factors
- Gastrointestinal Agents
- Adjuvants, Immunologic
- Antacids
- Aluminum Hydroxide
Other Study ID Numbers
- VRC 313
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alphavirus Infections
-
International Vaccine InstituteActive, not recruitingChikungunyaColombia, Costa Rica, Guatemala, Panama, Thailand
-
Butantan InstituteValneva Austria GmbHActive, not recruiting
-
Bharat Biotech International LimitedCompleted
-
Valneva Austria GmbHCompleted
-
University of OxfordCompleted
-
University of OxfordCompletedChikungunya | ZikaMexico
-
Bavarian NordicEmergent BioSolutionsCompleted
-
Institute of Tropical Medicine, BelgiumWithdrawnChikungunya FeverBelgium, Aruba
-
Ology BioservicesCompletedProphylaxis of Ross River Virus InfectionAustralia
-
Bavarian NordicWalter Reed Army Institute of Research (WRAIR); Emergent BioSolutionsCompletedChikungunyaUnited States
Clinical Trials on VRC-WEVVLP073-00-VP
-
National Institute of Allergy and Infectious Diseases...Centers for Disease Control and Prevention; International AIDS Vaccine Initiative and other collaboratorsWithdrawn
-
National Institute of Allergy and Infectious Diseases...HIV Vaccine Trials NetworkCompleted
-
National Institute of Allergy and Infectious Diseases...United States Department of DefenseCompletedHIV InfectionsUganda, Kenya, Tanzania
-
National Institute of Allergy and Infectious Diseases...Completed
-
National Institute of Allergy and Infectious Diseases...HIV Vaccine Trials NetworkCompleted
-
National Institute of Allergy and Infectious Diseases...CompletedHealthy Adult Immune Responses to VaccineUnited States
-
National Institute of Allergy and Infectious Diseases...Completed
-
National Institute of Allergy and Infectious Diseases...CompletedRNA Virus Infections | Virus Diseases | Flavivirus Infections | Flaviviridae Infections | Zika Virus Infection | Zika Virus | Flaviviral DiseasesUnited States, Puerto Rico, Mexico, Brazil, Colombia, Costa Rica, Ecuador, Panama, Peru
-
National Institute of Allergy and Infectious Diseases...CompletedHIV Infections | HealthyUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedTrial for Safety and Immunogenicity of a Chikungunya Vaccine, VRC-CHKVLP059-00-VP, in Healthy AdultsChikungunya Virus InfectionDominican Republic, Puerto Rico, Guadeloupe, Haiti, Martinique